{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:57:29Z","timestamp":1793275049547,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with alpha-1 antitrypsin deficiency (AATD), commonly categorized as a rare disease, have been affected by the changes in healthcare management brought about by COVID-19. This study\u2019s aim was to identify the changes that have taken place in AATD patient care as a result of the COVID-19 pandemic in Spain and to propose experts\u2019 recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A qualitative descriptive case study with a holistic single-case design was conducted, using focus groups with experts in AATD clinical management, including 15 health professionals with ties to the Spanish health system (12 pneumologists and 2 hospital pharmacists from 11 different hospitals in Spain) and 1 patient representative.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>COVID-19 has had a major impact on numerous aspects of AATD clinical patient management in Spain, including diagnostic, treatment, and follow-up phases. The experts concluded that there is a need to strengthen coordination between Primary Care and Hospital Care and improve the coordination processes across all the organizations and actors involved in the healthcare system. Regarding telemedicine and telecare, experts have concluded that it is necessary to promote this methodology and to develop protocols and training programs. Experts have recommended developing personalized and precision medicine, and patient participation in decision-making, promoting self-care and patient autonomy to optimize their healthcare and improve their quality of life. The possibility of monitoring and treating AATD patients from home has also been proposed by experts. Another result of the study was the recommendation of the need to ensure that plasma donations are made on a regular basis by a sufficient number of healthy individuals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The study advances knowledge by highlighting the challenges faced by health professionals and changes in AATD patient management in the context of the COVID-19 pandemic. It also proposes experts\u2019 recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation. This work could serve as a reference study for physicians on their daily clinical practice with AATD patients and may also provide guidance on the changes to be put in place for the post-pandemic situation.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-023-09094-3","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T07:03:34Z","timestamp":1675062214000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["COVID-19\u2019s impact on care practice for alpha-1-antitrypsin deficiency patients"],"prefix":"10.1186","volume":"23","author":[{"given":"Myriam","family":"Calle Rubio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Michel de la Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Hern\u00e1ndez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Montero Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Bruno","family":"Montoro Ronsano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Casas Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Rodr\u00edguez Hermosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Mar\u00eda","family":"Tabernero Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Mart\u00ednez Sesmero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mart\u00ednez Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Callejas Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Torres Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"issue":"3","key":"9094_CR1","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1093\/pubmed\/fdab102","volume":"43","author":"V Chiesa","year":"2021","unstructured":"Chiesa V, Antony G, Wismar M, Rechel B. COVID-19 pandemic: health impact of staying at home, social distancing and \u201clockdown\u201d measures-a systematic review of systematic reviews. J Public Health (Oxf). 2021;43(3):e462\u201381.","journal-title":"J Public Health (Oxf)"},{"key":"9094_CR2","doi-asserted-by":"publisher","first-page":"640282","DOI":"10.3389\/fpubh.2021.640282","volume":"9","author":"SF Chowdhury","year":"2021","unstructured":"Chowdhury SF, Al Sium SM, Anwar S. Research and management of rare diseases in the COVID-19 pandemic era: challenges and countermeasures. Front public Heal. 2021;9:640282.","journal-title":"Front public Heal"},{"issue":"1","key":"9094_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s13023-020-01619-x","volume":"15","author":"C Lampe","year":"2020","unstructured":"Lampe C, Dionisi-Vici C, Bellettato CM, Paneghetti L, LingenBond CvanS, et al. The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys. Orphanet journal of rare diseases. 2020;15(1):341.","journal-title":"Orphanet journal of rare diseases"},{"issue":"3","key":"9094_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41584-020-00565-z","volume":"17","author":"R Talarico","year":"2021","unstructured":"Talarico R, Aguilera S, Alexander T, Amoura Z, Antunes AM, Arnaud L, et al. The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. Nat Rev Rheumatol. 2021;17(3):177\u201384.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"9094_CR5","first-page":"668","volume":"3","author":"RA Sandhaus","year":"2016","unstructured":"Sandhaus RA, Turino G, Brantly ML, Campos M, Cross CE, Goodman K, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis (Miami, Fla). 2016;3(3):668\u201382.","journal-title":"Chronic Obstr Pulm Dis (Miami, Fla)"},{"issue":"7","key":"9094_CR6","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.3390\/ijerph17072294","volume":"17","author":"A Sanduzzi","year":"2020","unstructured":"Sanduzzi A, Ciasullo E, Capitelli L, SanduzziZamparelli S, Bocchino M. Alpha-1-antitrypsin deficiency and bronchiectasis: a concomitance or a real association? Int J Environ Res Public Health. 2020;17(7):2294.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"9094_CR7","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1164\/ajrccm\/140.4.961","volume":"140","author":"EK Silverman","year":"1989","unstructured":"Silverman EK, Miletich JP, Pierce JA, Sherman LA, Endicott SK, Broze GJJ, et al. Alpha-1-antitrypsin deficiency. high prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis. 1989;140(4):961\u20136.","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"9094_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3109\/15412555.2012.669433","volume":"9","author":"FF Rahaghi","year":"2012","unstructured":"Rahaghi FF, Sandhaus RA, Brantly ML, Rouhani F, Campos MA, Strange C, et al. The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. COPD. 2012;9(4):352\u20138.","journal-title":"COPD"},{"issue":"6","key":"9094_CR9","doi-asserted-by":"publisher","first-page":"1700610","DOI":"10.1183\/13993003.01441-2020","volume":"56","author":"T Nakanishi","year":"2020","unstructured":"Nakanishi T, Forgetta V, Handa T, Hirai T, Mooser V, Lathrop GM, et al. The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes. Eur Respir J. 2020;56(6):1700610.","journal-title":"Eur Respir J"},{"issue":"5","key":"9094_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/1753465810376407","volume":"4","author":"T K\u00f6hnlein","year":"2010","unstructured":"K\u00f6hnlein T, Janciauskiene S, Welte T. Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency. Ther Adv Respir Dis. 2010;4(5):279\u201387.","journal-title":"Ther Adv Respir Dis"},{"key":"9094_CR11","doi-asserted-by":"publisher","first-page":"110394","DOI":"10.1016\/j.mehy.2020.110394","volume":"146","author":"X Bai","year":"2021","unstructured":"Bai X, Hippensteel J, Leavitt A, Maloney JP, Beckham D, Garcia C, et al. Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19. Med Hypotheses. 2021;146:110394.","journal-title":"Med Hypotheses"},{"issue":"2","key":"9094_CR12","doi-asserted-by":"publisher","first-page":"e2157","DOI":"10.1002\/rmv.2157","volume":"31","author":"MB de Loyola","year":"2021","unstructured":"de Loyola MB, Dos Reis TTA, de Oliveira GXLM, da Fonseca PJ, Arga\u00f1araz GA, Arga\u00f1araz ER. Alpha-1-antitrypsin: a possible host protective factor against Covid-19. Rev Med Virol. 2021;31(2):e2157.","journal-title":"Rev Med Virol"},{"key":"9094_CR13","doi-asserted-by":"publisher","unstructured":"Azouz NP, Klingler AM, Callahan V, Akhrymuk IV, Elez K, Raich L, et al. Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2. bioRxiv. 2020:2020.05.04.077826. https:\/\/doi.org\/10.1101\/2020.05.04.077826. Update in: Pathog Immun. 2021 Apr 26;6(1):55\u201374.","DOI":"10.1101\/2020.05.04.077826"},{"issue":"1","key":"9094_CR14","doi-asserted-by":"publisher","first-page":"1600154","DOI":"10.1183\/13993003.00154-2016","volume":"49","author":"T Greulich","year":"2017","unstructured":"Greulich T, Nell C, Hohmann D, Grebe M, Janciauskiene S, Koczulla AR, et al. The prevalence of diagnosed \u03b11-antitrypsin deficiency and its comorbidities: results from a large population-based database. Eur Respir J. 2017;49(1):1600154.","journal-title":"Eur Respir J"},{"issue":"12","key":"9094_CR15","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/clc.23465","volume":"43","author":"L Luo","year":"2020","unstructured":"Luo L, Fu M, Li Y, Hu S, Luo J, Chen Z, et al. The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis. Clin Cardiol. 2020;43(12):1478\u201393.","journal-title":"Clin Cardiol"},{"issue":"4","key":"9094_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2213-2600(21)00018-7","volume":"9","author":"C Yang","year":"2021","unstructured":"Yang C, Chapman KR, Wong A, Liu M. \u03b11-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action. Lancet Respir Med. 2021;9(4):337\u20139.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"9094_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Heal care J Int Soc Qual Heal Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Heal care J Int Soc Qual Heal Care"},{"issue":"2","key":"9094_CR18","doi-asserted-by":"publisher","first-page":"e000074","DOI":"10.1136\/fmch-2018-000074","volume":"7","author":"S F\u00e0bregues","year":"2019","unstructured":"F\u00e0bregues S, Fetters MD. Fundamentals of case study research in family medicine and community health. Fam Med community Heal. 2019;7(2):e000074.","journal-title":"Fam Med community Heal"},{"key":"9094_CR19","volume-title":"Qualitative inquiry and research design choosing among five approaches","author":"JW Creswell","year":"2018","unstructured":"Creswell JW, Poth CN. Qualitative inquiry and research design choosing among five approaches. 4th ed. Thousand Oaks: SAGE Publications, Inc.; 2018.","edition":"4"},{"issue":"1","key":"9094_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/13814788.2017.1375091","volume":"24","author":"A Moser","year":"2018","unstructured":"Moser A, Korstjens I. Series: Practical guidance to qualitative research. Part 3: Sampling, data collection and analysis. Eur J Gen Pract. 2018;24(1):9\u201318.","journal-title":"Eur J Gen Pract"},{"issue":"Supplement","key":"9094_CR21","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.4103\/lungindia.lungindia_685_20","volume":"38","author":"SS Salvi","year":"2021","unstructured":"Salvi SS, Dhar R, Mahesh PA, Udwadia ZF, Behra D. COPD management during the COVID-19 pandemic. Lung India. 2021;38(Supplement):S80\u20135.","journal-title":"Lung India"},{"issue":"36","key":"9094_CR22","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.15585\/mmwr.mm6936a4","volume":"69","author":"M\u00c9 Czeisler","year":"2020","unstructured":"Czeisler M\u00c9, Marynak K, Clarke KEN, Salah Z, Shakya I, Thierry JM, et al. Delay or avoidance of medical care because of COVID-19-related concerns - United States, June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(36):1250\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"9094_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.rmed.2008.10.006","volume":"103","author":"LS Aboussouan","year":"2009","unstructured":"Aboussouan LS, Stoller JK. Detection of alpha-1 antitrypsin deficiency: a review. Respir Med. 2009;103(3):335\u201341.","journal-title":"Respir Med"},{"key":"9094_CR24","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.2147\/COPD.S268421","volume":"15","author":"E Pleguezuelos","year":"2020","unstructured":"Pleguezuelos E, Del Carmen A, Moreno E, Ortega P, Vila X, Ovejero L, et al. The experience of COPD patients in lockdown due to the COVID-19 pandemic. Int J Chron Obstruct Pulmon Dis. 2020;15:2621\u20137.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"9094_CR25","first-page":"107","volume":"27","author":"BE Holtz","year":"2021","unstructured":"Holtz BE. Patients perceptions of telemedicine visits before and after the coronavirus disease 2019 pandemic. Telemed J e-health Off J Am Telemed Assoc. 2021;27(1):107\u201312.","journal-title":"Telemed J e-health Off J Am Telemed Assoc"},{"issue":"6","key":"9094_CR26","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/jcm10061261","volume":"10","author":"S Rutkowski","year":"2021","unstructured":"Rutkowski S. Management challenges in chronic obstructive pulmonary disease in the COVID-19 Pandemic: telehealth and virtual reality. J Clin Med. 2021;10(6):1261. https:\/\/doi.org\/10.3390\/jcm10061261.","journal-title":"J Clin Med."},{"issue":"12","key":"9094_CR27","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1097\/ACM.0000000000003711","volume":"95","author":"O Jumreornvong","year":"2020","unstructured":"Jumreornvong O, Yang E, Race J, Appel J. Telemedicine and medical education in the age of COVID-19. Acad Med. 2020;95(12):1838\u201343.","journal-title":"Acad Med"},{"key":"9094_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40670-020-01008-w","volume":"30","author":"SS Camhi","year":"2020","unstructured":"Camhi SS, Herweck A, Perone H. Telehealth training is essential to care for underserved populations: a medical student perspective. Med Sci Educ. 2020;30:1\u20134.","journal-title":"Med Sci Educ"},{"issue":"5","key":"9094_CR29","doi-asserted-by":"publisher","first-page":"e16147","DOI":"10.2196\/16147","volume":"8","author":"KG Fan","year":"2020","unstructured":"Fan KG, Mandel J, Agnihotri P, Tai-Seale M. Remote patient monitoring technologies for predicting chronic obstructive pulmonary disease exacerbations: review and comparison. JMIR mHealth uHealth. 2020;8(5):e16147.","journal-title":"JMIR mHealth uHealth"},{"key":"9094_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/1750-1172-8-149","volume":"8","author":"RA Stockley","year":"2013","unstructured":"Stockley RA, Miravitlles M, Vogelmeier C. Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis. 2013;8:149.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"9094_CR31","doi-asserted-by":"publisher","first-page":"00171","DOI":"10.1183\/23120541.00171-2018","volume":"5","author":"I Horv\u00e1th","year":"2019","unstructured":"Horv\u00e1th I, Canotilho M, Chlumsk\u00fd J, Chorostowska-Wynimko J, Corda L, Derom E, et al. Diagnosis and management of \u03b1(1)-antitrypsin deficiency in Europe: an expert survey. ERJ open Res. 2019;5(1):00171\u20132018.","journal-title":"ERJ open Res"},{"issue":"1","key":"9094_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/br.2017.922","volume":"7","author":"S Mathur","year":"2017","unstructured":"Mathur S, Sutton J. Personalized medicine could transform healthcare. Biomed Rep. 2017;7(1):3\u20135.","journal-title":"Biomed Rep"},{"issue":"7","key":"9094_CR33","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.3390\/ijerph18073480","volume":"18","author":"JA Garc\u00eda-Erce","year":"2021","unstructured":"Garc\u00eda-Erce JA, Rom\u00f3n-Alonso \u00cd, Jeric\u00f3 C, Domingo-Morera JM, Arroyo-Rodr\u00edguez JL, Sola-Lape\u00f1a C, et al. Blood donations and transfusions during the COVID-19 pandemic in spain: impact according to autonomous communities and hospitals. Int J Environ Res Public Health. 2021;18(7):3480.","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"9094_CR34","doi-asserted-by":"publisher","first-page":"1700610","DOI":"10.1183\/13993003.00610-2017","volume":"50","author":"M Miravitlles","year":"2017","unstructured":"Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, et al. European respiratory society statement: diagnosis and treatment of pulmonary disease in \u03b1(1)-antitrypsin deficiency. Eur Respir J. 2017;50(5):1700610.","journal-title":"Eur Respir J"},{"issue":"2","key":"9094_CR35","first-page":"79","volume":"18","author":"X Cai","year":"2020","unstructured":"Cai X, Ren M, Chen F, Li L, Lei H, Wang X. Blood transfusion during the COVID-19 outbreak. Blood Transfus. 2020;18(2):79\u201382.","journal-title":"Blood Transfus"},{"issue":"8","key":"9094_CR36","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1111\/trf.16422","volume":"61","author":"X Delabranche","year":"2021","unstructured":"Delabranche X, Kientz D, Tacquard C, Bertrand F, Roche A-C, Tran Ba Loc P, et al. Impact of COVID-19 and lockdown regarding blood transfusion. Transfusion. 2021;61(8):2327\u201335.","journal-title":"Transfusion"},{"issue":"2","key":"9094_CR37","first-page":"1","volume":"20","author":"E Bernal-Delgado","year":"2018","unstructured":"Bernal-Delgado E, Garcia-Armesto S, Oliva J, SanchezMartinez FI, Repullo JR, Pena-Longobardo LM, et al. Spain: health system review. Health Syst Transit. 2018;20(2):1\u2013179.","journal-title":"Health Syst Transit"},{"key":"9094_CR38","doi-asserted-by":"crossref","unstructured":"Vargas Lorenzo I, V\u00e1zquez Navarrete ML. [Barriers and facilitators to health care coordination in two integrated health care organizations in Catalonia (Spain)].Gac Sanit. 2007;21(2):114\u201323.","DOI":"10.1157\/13101037"},{"key":"9094_CR39","unstructured":"Garc\u00eda-Armesto S, Bego\u00f1a Abad\u00eda-Taira M, Dur\u00e1n A, Hern\u00e1ndez-Quevedo C, Bernal-Delgado E. Spain: health system review. Health Syst Transit. 2010;12(4):1\u2013295, xix\u2013xx."},{"key":"9094_CR40","doi-asserted-by":"crossref","unstructured":"Fulcher MR, Bolton ML, Millican MD, Michalska-Smith MJ, Dundore-Arias JP, Handelsman J, et al. Broadening participation in scientific conferences during the era of social distancing. Trends Microbiol. 2020;28(12):949\u201352.","DOI":"10.1016\/j.tim.2020.08.004"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09094-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-023-09094-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09094-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T07:09:50Z","timestamp":1675062590000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-023-09094-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["9094"],"URL":"https:\/\/doi.org\/10.1186\/s12913-023-09094-3","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"20 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed following the Helsinki Declaration. The study was conducted according to national regulations, as described by Royal Decree 1090\/2015. According to the aforementioned legislation, due to the nature of the study, approval by an ethics committee was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not aplicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MC has received speaking fees from Boehringer Ingelheim, CSL Behring, AstraZeneca, GlaxoSmithKline, Griffols, Menarini, and Novartis and consulting fees from GlaxoSmith\u00adKline, Gebro Pharma and Novartis. JLLC has received honoraria for lecturing, scientific advice, participation in clinical studies or writing for publications for AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, CSL Behring, Ferrer, Gebro, GlaxoSmithKline, Grifols, Menarini, Megalabs, Novartis and Rovi. MM has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Inhibrx, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, Spin Therapeutics, ONO Pharma, pH Pharma, Palobiofarma SL, Takeda, Novartis, Sanofi and Grifols and research grants from Grifols. FJMDLR has received speaker fees and\/or consulting fees and\/or support to attend Congresses from AstraZeneca, Boehringer-Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Grifols, Menarini, Novartis, Sanofi and Teva. JMHP has received speaker fees from GRIFOLS, CSL Behring, GSK, Astra-Zeneca, Menarini Laboratories, Boehringer Ingelheim, FAES, Esteve Laboratories, Ferrer Laboratories, Mundipharma, Rovi Laboratories, Roche, Novartis, Pfizer, Acthelion-Jansen, Chiesi and Bial Laboratories for the conducting courses, talks, consultancies and other activities related to my professional activity. CMM has received speaking and consulting fees from CSL Behring and\u00a0Grifols. JBMR has received speaker fees and\/or consulting fees and\/or support to attend Congresses from CSL Behring, NovoNordisk, Grifols, Pfizer, Biotest and Takeda. FCM has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Glaxo Smith Klein, Grifols and Novartis, consulting fees from AstraZeneca, Glaxo Smith Kline, CSL Behring, Sanofi and Grifols. JLRH has received speaker fees from CSL\u00a0Behring and Grifols, and\u00a0research grants from Grifols. ET has received consulting fees from CSL Behring. JMMS has received honoraria for conducting courses and consultancy from CSL Behring. CMR has received honoraria during the last 3\u00a0years for lecturing, scientific advice and participation in clinical studies from Glaxo SmithKline, Astra Zeneca, TEVA, Sanophi, CSL Behring, Mundipharma, Chiesi, Orion and Novartis. FJCG has received honoraria during the last 3\u00a0years for lecturing and scientific advice from GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Mundipharma, Pfizer, Novartis, Esteve, Teva Pharmaceutical, Ferrer, Rovi, Roche, Astra Zeneca, Bial, Actelion, Alter, CSL Behring, Faes Farma, Alter, Grifols, Sanofi Genzyme y Gebro Pharma. MTD has received speaking and consulting fees from CSL Behring and Grifols.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}